Скачать с ютуб CALQUENCE® (acalabrutinib) Pooled Safety Analysis – Dr Pinilla-lbarz, MD в хорошем качестве

CALQUENCE® (acalabrutinib) Pooled Safety Analysis – Dr Pinilla-lbarz, MD

Please see Full Prescribing Information: https://bit.ly/3Ly3ru0 This video is intended for US healthcare professionals only. Javier Pinilla-lbarz, MD, PhD discusses key findings from a pooled analysis of select cardiovascular events across four studies in patients with chronic lymphocytic leukemia (CLL) taking CALQUENCE. Topics include overview of the methodology of the analysis, cardiovascular risk factors, detailed review of atrial fibrillation and hypertension data, and incidence of select cardiac adverse events. Select Safety Information CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions (≥30%) of any grade in patients with CLL were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.